Extraordinary people find extraordinary
According to incomplete statistics, after 2000, there are at least dozens of clinical trials of drugs for the treatment of tumor/cancer groups in the world every year. However, so far, no long-term radical tumor/cancer group drugs have been found, because the DNA sequence of normal cells of each tumor/cancer patient is different, and tumor cells, cancer cells and their derivatives are all mutated from normal cells. Population drugs cannot distinguish the differences between multiple pathogenic molecules/multiple pathogenic cells and normal molecules/normal cells of a cancer patient.
There are many reasons why cancer cannot be cured.
First of all, the tumor cancer of each cancer is different, and there are a variety of causes that vary from person to person. Macroscopically, malignant tumors, metastatic tumors, and microcarcinomas can be seen by the naked eye through images. Microscopically, through biopsy and liquid biopsy, Mutant cells, tumor cells, cancer cells and their derivatives, including exosomes, can be observed under the microscope. At the molecular level, these mutant cells, tumor cells, cancer cells and their derivatives, including exosomes, contain a variety of mutant DNA sequences, a variety of mutant RNA sequences and a variety of mutant protein sequences. At the immune level, they are a variety of new antigen-producing organisms of immune escape, including infection, etc. These causes increase and increase with time, and the disease condition deteriorates with time, the normal tissues, normal organs and normal systems of cancer patients are destroyed, the structure and function are abnormal, failure, and death is inevitable; secondly, the cancer treatment methods such as surgery, radiotherapy, chemotherapy, targeted drugs, cell drugs and traditional Chinese medicine are not aimed at the cause, only primary tumors, metastases, microcarcinomas, variant cells, tumor cells, cancer cells and their derivatives including circulating tumor cells (CTCs), exosomes, ctDNA, miRNAs, new antigen-producing organisms and infections cannot be precisely eliminated. Third, all etiologies share a common feature of immune escape. Current cancer treatment methods and drugs, with the exception of ATATES and AMAMES new anti-patent products, do not target this feature.
Tumor surgery can only remove the local tumor
Metastatic tumors and some lymph nodes, microcarcinomas that cannot be resected and metastasized to other sites, and cancer cells and their derivatives that metastasize to the blood, including circulating tumor cells (CTCs), exosomes, ctDNA, miRNAs, new antigens, and infections. These minimal residual disease (MRD) is the main source of recurrence, secondary, new onset, cachexia and "people and money. It is characterized by the increasing number of metastatic microcarcinomas, microcellular lesions and molecular lesions over time, the continuous transformation of normal cells into cancer cells and the continuous immune escape, recurrence, secondary, new onset, uncontrolled metastasis, cachexia and system failure, and inevitable death.
Generally, tumor radiotherapy can only burn local tumor cells and cancer cells, reduce the volume of primary tumor and metastatic tumor, cannot be used for the second time in the same part (fatal), and cannot burn small cancer tumors transferred to other parts and cancer cells transferred to blood and their derivatives including infection, etc. After radiotherapy, normal cells may also form tumors after 6 months to 3 years. Not burned and new tumor cells, cancer cells and their derivatives and infection are the main causes of recurrence, secondary, new, cachexia and "money and money. It is characterized by the increasing number of metastatic microcarcinomas, microcellular foci and molecular foci over time, uncontrolled mutations, constant transformation of normal cells into cancer cells, uncontrolled transformation, constant immune escape, uncontrolled immune escape, recurrence, secondary, new, uncontrolled metastasis, cachexia and system failure, and death is inevitable.
Chemotherapeutic drugs poison tumor cells that grow out of control, shrink tumors (including primary and metastatic), but also poison fast-growing normal cells, especially a variety of immune cells and stem cells, destroy the immune system, and cannot poison tumor cells that grow slowly but mutate out of control, cancer cells and their derivatives, including new antigen-producing organisms and infections. Can not poison the lesions, including macroscopic tumor, microcarcinoma and microscopic cancer cells and cancer molecular lesions, etc., to produce drug resistance, continue to grow, continue to transform normal cells into cancer cells and their derivatives. Some normal cells are fine after being poisoned by chemotherapy drugs, but a small number of half-dead cells may also become cancer cells and their derivatives. Drug-resistant and new-onset mutant cells, tumor cells, cancer cells and their derivatives and infections are the main causes of recurrence, secondary, new onset and cachexia. These causes increase over time and the destruction of the immune system leading to system failure is the main cause of "people and money. It is characterized by small cancer, small cell lesions and molecular lesions with time increasing, mutation out of control, continuous transformation of normal cells into cancer cells and derivatives, transformation out of control, immune system is constantly destroyed, immune escape out of control, recurrence, secondary, new, metastasis out of control, cachexia and system failure, death is inevitable.
The targeted drug poisons mutant cells, tumor cells and normal cells with normal molecular targets (e. g. EGFR, PD1/PDL1, CD19.) that grow out of control, and cannot poison mutant cells, tumor cells, cancer cells and their derivatives and infections that do not have a target but grow and mutate out of control.
Can not poison the lesions, including the macro primary tumor lesions, metastatic lesions and small cancer, microscopic cell lesions and molecular lesions, drug resistance, continue to grow, continue to mutate, continue to transform normal cells into cancer cells. Drug-resistant mutant cells, tumor cells, cancer cells and their derivatives and infections are the main sources of recurrence, secondary, onset and cachexia. The killing of these causes and targeted drugs on targeted cells (including stem cells, etc.) is the main reason for "money and money. It is characterized by the fact that large tumors may shrink but metastatic lesions, small carcinomas, small cell lesions and molecular lesions are increasing over time, mutations are out of control, and normal cells are constantly transformed into cancer cells and derivatives, and the life system is degraded, leading to system failure and inevitable death. For example, advanced targeting drugs Erbitux, Keytruda and Kymriah target EGFR,PD-1/PDL-1 and CD19 targets, respectively, which are not pathogenic molecules but normal molecules. Because these targeted drugs do not target pathogenic molecules but normal molecules, there are major problems such as limited efficacy, drug resistance, toxic and side effects, and degradation of patients' life systems, such as intolerance, irrationality and non-compliance.
Cellular drugs, including stem cells, DC/CIK, NK, granulocyte and CAR-T, are part of the immune system, but they cannot represent the immune system and cannot enhance the function of the immune system. On the contrary, they break the balance of different division of labor and proportions of various immune cells in the immune system, causing fever, high fever, pain and other toxic side effects that attack normal cells. The key is not to target any of the various causes. Lesions that cannot be cleared by immune cells, including macroscopic primary tumor lesions, metastatic lesions, microcarcinomas, and microscopic cellular and molecular lesions, produce drug resistance or immune escape, continue to grow wildly, continue to mutate, and continue to transform normal cells into cancer cells and their derivatives. Drug resistance or immune escape of tumor cells, cancer cells and their derivatives and infection is the main source of secondary recurrence, new onset and cachexia. These causes and the interference and destruction of the immune system by cell drugs are the main reasons for the "empty of people and money.
Extraordinary people, extraordinary inventions, extraordinary theories, extraordinary applications
According to the common characteristics of immune escape of various causes, Dr. Qian Yong and his team invented the patented products of ATATES and AMAMES neoantigens, which are privately customized with the patient's life system as the center. Under reasonable, reasonable and compliant conditions, they successfully conquered the major problems of immune escape of various causes and subverted the cognition of human beings in treating cancer and other diseases.
Therefore, the use of ATATES and AMAMES neoantigen patented products is characterized on the basis of reasonableness, reasonableness and compliance.
1) ATATATES and AMAMES new antigen patented products are used to accurately target a variety of causes, including primary tumors, metastatic tumors, microcarcinomas, tumor cells, cancer cells and their derivatives, including blood circulating tumor cells (CTC), exosomes, ctDNA, miRNA, new antigen-producing organisms and infections, etc., without accidentally injuring any normal molecules or normal cells, no injury to any normal tissue, no injury to any normal organs, no injury to any normal system.
2) Overcome surgery, radiotherapy, chemotherapy, targeted drugs, cell drugs and traditional Chinese medicine, etc. do not target the cause, only for growth out of control, not for mutation out of control, limited efficacy, drug resistance, toxic and side effects, do not protect the normal life system and make the normal life system degradation and other unreasonable, unreasonable and non-compliant problems.
3) Make a variety of causes no longer immune escape, short-term and long-term immune clearance of all new antigen-producing organisms, of course, the customer's lesions including primary tumor lesions, metastatic lesions, small cancer tumors and small cell lesions and molecular lesions and infection and other causes are also clear 0, a variety of tumor markers returned to normal.
4) Make the client long-term (more than 10 years) disease-free survival, because the mutation caused by the susceptibility gene is cleared by long-term immunity, and it is cleared by immunity immediately when it recurs.
Because ATATES and AMAMES new antigen patented products target a variety of causes such as mutation, variation or infection of a person without targeting any normal system/organ/tissue/cell/molecule, it overcomes the limitations of surgery, radiotherapy, chemotherapy, targeted drugs, cell drugs and traditional Chinese medicine that do not follow the natural laws of their life systems, it has the characteristics of protecting normal life system, aiming at etiology, multiple curative effects, long-term curative effects, superimposed curative effects, no drug resistance, no toxic and side effects, and making normal life system evolution and strengthening reasonable, reasonable and compliant. The research results show that more than 90% of patients with middle and advanced cancer and other diseases, sub-health and infection with sound normal life system can survive for a long time (more than 10 years) without disease after using customized ATATES and AMAMES new antigen patented products to immunize all causes, and B cells with long-term memory of new antigen are new qualitative productivity, A variety of variant molecules/variant cells and their derivatives or infections caused by susceptible genes can be eliminated in a timely and efficient manner.
Extraordinary scientific research achievements
High-end customers who pursue long-term removal of multiple causes play an important role in the process of cooperation, mainly in
1) The main limitation of understanding group medicine is that it does not take into account the differences in the genetic material of different human DNA and the differences in different life systems determined by it.
2) Understand the value of personalized high-end medical "long-term immunity to eliminate multiple causes", scientific, repeatable, quantifiable, statistical, no group drug uncertainty.
3) know the immune elimination of a variety of causes of the premise.
4) Know the specific process of using customized ATATES and AMAMES new antigen patented products for long-term immune clearance of multiple causes including multiple mutant cells, various tumor cells, various types of cancer cells and their derivatives, and infections,
5) understand the economic value of customized ATATES and AMAMES new antigen patent product development and access to health, access to new life.
Enterprises that customize new antigen patented products, such as BioMedicure, are in the position of cooperative research and development services. At the request of customers, with the samples provided by customers, ATATES and AMAMES new antigen patented products are customized for customers with multiple causes, no drug resistance, no toxic side effects and the evolution of their life systems according to new antigens. The process of customizing ATATES and AMAMES new antigen patented products is simply to make various mutant cells, tumor cells, cancer cells and their derivatives and infections in tumor tissues or blood samples provided by customers into LNP sphere patented products with the world's leading technology through the patented technology invented by BioMedicure. The spheres in the sphere product contain a variety of new antigen-producing organisms derived from mutated cells, tumor cells, cancer cells and their derivatives, and infections. These causes have a variety of active ingredients: New Antigen 1, New Antigen 2 .. New Antigen N. After using the new antigen patented products, the customer's sound immune system obtains a variety of new antigen active ingredients, according to the new antigen synthesis of new antigen receptor T cells, new antigen receptor plasma cells and polyclonal antibodies against the new antigen. These 3 types of active cells or macromolecules in the customer's body immune kill with the new antigen to produce biological variants, variant cells, tumor cells, cancer cells and their derivatives and infections, so that they no longer immune escape! Efficacy is proportional to the number of new antigen producers in the product. Multiple courses of different new antigen products can be superimposed on the efficacy of the customer's body variant molecules, variant cells, tumor cells, cancer cells and their derivatives and infections such as clear 0, reverse the process of cancer development. Multiple, long-term, and additive efficacy are key to short-and long-term eradication of cancer. Because normal molecules, normal cells and their derivatives do not have any new antigens, they will not be accidentally injured, and the clinical manifestations are free of any toxic and side effects. The immune system has long-term memory of new antigens in the form of new antigen receptor B cells, exerting long-term efficacy and superimposed efficacy, and continuously improving quantifiable immunity.
ATATES and AMAMES meet the high-end needs of high-end customers "for multiple etiologies"
Cancer treatment methods such as surgery, radiotherapy, chemotherapy, targeted drugs, cell drugs and traditional Chinese medicine are only aimed at eliminating/removing/reducing local tumors, not at pathogenic molecules/pathogenic cells, and cannot accurately eliminate only mutated cells, tumor cells, cells and their derivatives, infections and other causes. The 10 year disease free survival rate was 0. Customization and use of ATATES and AMAMES new antigen patented products of high-end medical 100 for the cause of disease, targeting a variety of new antigen-producing organisms contained in cells or molecules such as mutated cells, tumor cells, cancer cells and their derivatives (such as CTCs, exosomes, circulating DNA and miRNAs, etc.) and infections, so that they no longer escape, without accidentally injuring any normal molecule/normal cell/normal tissue/normal organ/normal system. ATATES and AMAMES new antigen patented products meet the high-end needs of high-end customers "for multiple causes", and the disease-free survival rate of high-end customers with sound immune system is more than 90% for more than 10 years.
ATATES and AMAMES meet the needs of high-end customers "to protect normal life systems"
Surgery, radiotherapy, chemotherapy, targeted drugs, cell drugs and traditional Chinese medicine and other treatment methods are not aimed at the cause of the molecular/cell, "the enemy is not distinguished", inevitably destroy the normal life system, the quality of life of patients in the process of treatment is good or poor. For example, after thoracotomy for lung cancer, the patient's physical strength can only be restored to about 60% of the preoperative. Coupled with the comprehensive treatment of radiotherapy, chemotherapy, targeted drugs, cell drugs and traditional Chinese medicine, the physical strength has further declined. The reason is that these therapies can not meet the needs of patients to "protect the normal life system.
Customized and high-end medical treatment using ATATES and AMAMES new antigen patented products is aimed at the cause (various new antigen-producing organisms), and precisely eliminates only mutant cells, tumor cells, cancer cells and their derivatives or infections, etc., without accidentally injuring any normal molecules/normal cells/normal tissues/normal organs/normal systems. This is achieved by the patient's sound immune system using the ATATES and AMAMES new antigen patented products for antigen presentation. Stem cells, DC cells, macrophages, NK cells and granulocytes, which constitute the immune system, alone or in combination, cannot achieve the function of the entire immune system because of the lack of a source of new antigens. The use of stem cells, DC cells, macrophages, NK cells, and granulocytes, among others, is characterized by fever, fever, and pain, as normal cells are attacked by immune cells. The use of ATATES and AMAMES new antigen patented products has no side effects such as fever, fever and pain, and fully meets the high-end needs of high-end customers to "protect normal life systems.
ATATES and AMAMES meet the high-end needs of high-end customers with "multiple long-term effects"
Surgery, radiotherapy, chemotherapy, targeted drugs, cell drugs and traditional Chinese medicine and other cancer treatment methods do not target a variety of pathogenic molecules/cells, do not target the complex disease, the lack of accurate elimination of all tumor cells, cancer cells and their derivatives and infections and other "a variety of long-term efficacy", therefore, the more lesions treated, death is inevitable. Customized and high-end medical treatment using ATATES and AMAMES new antigen patented products aims at a variety of causes (various new antigen-producing organisms), using new antigen polyclonal antibodies and new antigen receptor B cells and other short-term and long-term immunization to kill various variant cells, tumor cells, cancer cells and their derivatives and infections, without accidentally injuring any normal molecules/normal cells/normal tissues/normal organs/normal systems. Patients in the use of ATATES and AMAMES new antigen patent products in the high-end medical process can be long-term elimination of various etiological molecules/etiological cells, so that the lesions are less and less, the body is more and more strong, because fully meet the high-end customers "a variety of long-term curative effect" high-end demand.
ATATES and AMAMES meet the high-end needs of high-end customers "long-term superimposed efficacy"
Comprehensive cancer treatment methods such as surgery, radiotherapy, chemotherapy, targeted drugs, cell drugs and traditional Chinese medicine not only lack the "multiple long-term efficacy" of accurately eliminating a variety of mutated cells, tumor cells, cancer cells and their derivatives, but also lack the "long-term superimposed efficacy", because they ignore the natural laws of the immune system that vary from person to person and do not use the long-term memory function of B cells to remember new antigens.
Customized and high-end medical using ATATES and AMAMES neoantigen patented products target multiple etiologies (various neoantigen-producing organisms), following the natural laws of normal living systems, especially the immune system. With the function of immune system antigen presentation, various new antigens are continuously acquired and long-term memory in B cells in the form of new antigen receptors. Therefore, the evolved immune system can immunologically clear various variant cells, tumor cells, cancer cells and their derivatives, infections, etc. for a long time without accidentally injuring any normal molecules/normal cells/normal tissues/normal organs/normal systems. Patients in the use of ATATES and AMAMES new antigen patented products in the high-end medical process can be long-term elimination of various pathogenic molecules/pathogenic cells, the focus is less and less, and finally clear 0, because fully meet the high-end customers "a variety of long-term superimposed efficacy" of high-end needs.
ATATES and AMAMES meet the high-end needs of high-end customers "non-toxic side effects"
Advanced targeted drugs Erbitux, Keytruda and Kymriah target EGFR,PD-1/PDL-1 and CD19 targets, respectively, which are not causative but normal molecules. These targeted drugs kill targeted tumor cell populations while also killing normal cells that express these targets, regardless of the enemy or the enemy. For example, the toxic side effect of Erbitux is skin rash, as normal cells expressing EGFR subcutaneously are Erbitux killed. For another example, PD-1/PDL-1 immunosuppressants Keytruda allow patients' immune cells to attack normal cells that express PDL-1, resulting in hundreds of toxic side effects that vary from person to person.
For another example, Kymriah targeting CD19 targets and eliminating B cells with CD19 targets, the immunity of patients with long-term memory in B cells for various pathogens, viruses, bacteria, and fungi is all lost, and most patients eventually die of infection.
Customizing and using ATATES and AMAMES new antigen patented products for high-end medical treatment aims at various causes (various new antigen-producing organisms, originating from genome variation or infection, etc.), follows the natural laws of normal life systems, especially the immune system, and does not accidentally injure any normal molecules (products of about 28000 genes) and normal cells of a person. Therefore, it meets the high-end needs of "non-toxic side effects" of high-end customers.
ATATES and AMAMES meet the high-end needs of the customer "life system evolution"
Targeted drugs Erbitux, Keytruda and Kymriah target EGFR,PD-1/PDL-1 and CD19 normal molecular targets respectively. While killing the targeted tumor cell population, they also kill the normal cells expressing these targets regardless of the enemy or the enemy. After destroying the normal tissues/normal organs/normal systems in which these cells participate, the structure and function of the normal living system of cancer patients will deteriorate because of the expression of normal molecule EGFR, normal cells of PDL-1 and CD19 are killed by targeted drugs, the corresponding functions are also lost, and the living system is degraded.
Customization and use of ATATES and AMAMES new antigen patented products for high-end medical treatment for a variety of causes (a variety of new antigen-producing organisms, derived from genomic variation or infection, etc.), follow the normal life system, especially the natural law of the immune system, with the lymph node in the self-antigen receptor T cell library to protect any normal molecules and cells of the normal life system from any accidental injury. Therefore, ATATES and AMAMES new antigen patented products meet the high-end needs of high-end customers "life system evolution.
ATATES and AMAMES meet customers' high-end needs for "more powerful normal life systems"
Targeted drugs (e. g., Erbitux, Keytruda, and Kymriah targeting EGFR,PD-1/PDL-1, and CD19 normal molecular targets, respectively) kill targeted tumor cell populations while also killing normal cells expressing these targets regardless of the enemy or the enemy, degrading the structure and function of the normal living system of the cancer patient, with the total structure and function of the normal living system being less than 100 percent. Decreased vitality, decreased physical strength and decreased immunity lead to a decline in quality of life.
Customized and high-end medical treatment using ATATES and AMAMES new antigen patented products aims at various causes (various new antigen-producing organisms, originating from genome variation or infection, etc.), follows the natural law of normal life system, especially the immune system, and uses the autologous antigen receptor worker cell bank in lymph nodes not only to protect any normal molecules and cells of normal life system from any accidental injury, but also to produce long-term memory immunity or neoplasm productivity in B cells, the total structure and total function of the normal living system is greater than 100%. More than 100 percent of the immune or new qualitative productivity to enhance the patient's vitality, physical strength and immunity, improve the quality of life of cancer patients. Therefore, ATATES and AMAMES new antigen patented products meet the high-end needs of high-end customers "more powerful normal life systems.
The 26 patients with advanced cancer who customized and used ATATES and AMAMES new antigen patented products 10 years ago have been disease-free for more than 10 years, and their patients who did not customize and use new antigen products have died painfully. Therefore, the value of neoantigen products in cancer patients is far greater than the value of the most advanced targeted drugs. The underlying reasons are that targeted drugs are limited to a single efficacy, short-term efficacy, failure to prevent recurrence, failure to prevent metastasis, and toxic side effects (e. g., disruption of normal living systems). In order to benefit more people, BioMedicure are willing to help eligible customers customize 100% of the new antigen patented products for their causes at the price of the best targeted drugs.
Therefore, the value of neoantigen products in cancer patients is far greater than the value of the most advanced targeted drugs. The fundamental reason lies in a variety of long-term superimposed efficacy, prevent recurrence, prevent metastasis, prevent secondary, prevent new hair, reverse cachexia non-toxic side effects, protect the normal life system, so that the normal life system is constantly evolving, so that the normal life system is more powerful, improve the quality of life, and regain health, happiness, happiness and longevity. The patient becomes a healthy person.
Facing the problems of the century, Qian Yong and his BioMedicure team used the most cutting-edge biotechnology as a means to use a sound immune system and neoantigen products to overcome cancer and other diseases. They have carried out extensive scientific practice and pioneering work., And made outstanding achievements. Centered on the patient's life system, using privately tailored ATATES and AMAMES new antigen patented products to upgrade the immune system with new antigens under reasonable, reasonable and compliant conditions for long-term immunization.
Eliminate a variety of causes, successfully overcome a variety of causes of immune escape of many major problems. Because he led the BioMedicure team to successfully bring the ATATES™"The neoantigen product was used to rescue multiple patients with advanced and terminal cancer to get a new life (more than 100 of them without any disease), and AMAMES™Patented products are used to help many patients with sub-health, infection and difficult diseases, and have received widespread attention at home and abroad, and have won honorary titles such as Outstanding Entrepreneur and Outstanding Person Medical Innovation Award. Because eligible customers customized the ATATES™and AMAMES™The patented product of the new antigen has the characteristics of 100 percent for genomic variation, multiple active ingredients, multiple therapeutic effects, long-term therapeutic effects, overlapping therapeutic effects of different courses of treatment, following the natural laws of the immune system, and not having any toxic and side effects on normal cells, tissues, organs and systems. by ATATES™The new antigen patented product cured 26 patients of their cancer over 10 years of disease-free survival. BioMedicure received the San Diego Enterprise Award (Biochemistry Laboratory Excellence Award for 5 consecutive years)
The medical research results of the BioMedicure team led by Dr. Qian Yong in the past 13 years show that with a sound immune system and personalized customized new antigen patented products, a variety of causes can be eliminated by short-term and long-term immunity, and a variety of diseases of a person can be cured in a reasonable, reasonable and compliant manner, including cancer (leukemia, multiple myeloma, peritoneal stromal tumor, lymphoma, melanoma, glioma, lung cancer, liver cancer, pancreatic cancer, esophageal cancer, gastric cancer, intestinal cancer, bladder cancer, breast cancer, prostate cancer, tonsil adenocarcinoma, thyroid cancer, cervical cancer, ovarian cancer, etc. with lymph node metastasis, liver metastasis and bone metastasis), brain atrophy, Alzheimer's disease, uremia, Sjogren's syndrome, progressive freezing disease, insomnia, hypertension, hyperglycemia, hyperlipidemia, hyperlipidemia, high lipoprotein, gout, impotence, menstrual disorders, rheumatoid, arthritis, muscle weakness, cold constitution, atrial fibrillation, arrhythmia, coronary heart disease, diabetes, psoriasis, vitiligo and infection (COVID, HBV, HPV, EBV, mycoplasma, bacteria and fungi, etc.).
Tel: 021-50815370
Fax: 021-50815370
E-mail: admin@biomedicure.com
Address: Building 2, Lane 720, Cai Lun Road, and Building 10, Lane 198, Zhang Heng Road, China (Shanghai) Pilot Free Trade Zone
Pay attention to WeChat public number
Payment Scan Code Registered Member
See more in-station information